BioCentury | Sep 11, 2020
Translation in Brief

A compound to reduce adjuvanted vaccine side effects; an oncolytic virus to enable CAR T cells for solid tumors and more

...cytokines without compromising the vaccines’ immunogenicity or efficacy. City of Hope’s oncolytic virus-CAR T comboIn a paper in Science Translational Medicine, City of Hope...
...Priceman, an assistant professor in the department of hematology and hematopoietic cell transplantation, told BioCentury City of Hope...
...p50) – Nuclear factor of κ light polypeptide gene enhancer in B cells 1 BC Staff University of Chicago City of Hope University...
BioCentury | Aug 25, 2020
Management Tracks

Former head of gRED Varney joining Erasca; plus AAM, City of Hope, Immunovant, Kura, Illumina and more

...CEO of the National Pharmaceutical Council. The AAM represents generics and biosimilar manufacturers. Charles Brenner joined City of Hope...
...research department focused on the interface between cancer and diabetes in the U.S., according to City of Hope.Autoimmune...
...commercial officer. He was SVP, commercial North America at DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT). Robin Sawka Erasca Inc. City of Hope Kura...
BioCentury | Mar 7, 2020
Translation in Brief

Repurposing a protease inhibitor for COVID-19; plus City of Hope’s scorpion venom CAR T and Blaze’s tech for tissue-targeted steroid delivery

...cultured lung cells and other cell types. City of Hope’s chlorotoxin-based CAR T cells for glioblastoma A City of Hope...
...metalloproteinase 2 TMPRSS2 - Transmembrane protease serine 2 Hongjiang Li, Staff Writer, and Sandi Wong, Assistant Editor City of Hope Epidermal...
BioCentury | Feb 12, 2020
Tools & Techniques

NCATS, FDA meeting shines light on AAV manufacturing innovation

...amenable to high density culture systems. The latter were the focus of a presentation by City of Hope...
...of Health U.S. Food and Drug Administration (FDA) Touchlight Genetics Ltd. Cevec Pharmaceuticals GmbH Stanford University University of California San Francisco City of Hope gene...
BioCentury | Dec 14, 2019
Product Development

BCMA programs begin to find their niches

...study. Amrita Krishnan, director of the Judy and Bernard Briskin Center for Multiple Myeloma at City of Hope...
...all of these agents and it may mean that some are used sequentially.” Amrita Krishnan, City of Hope...
BioCentury | Nov 7, 2019
Clinical News

ALS group launches trial of digital app to track progression

...evaluate the benefits of acupuncture in recently diagnosed patients. TGen is an affiliate of the City of Hope. Erin...
BioCentury | Sep 30, 2019
Clinical News

Stable disease signal pushes Amgen KRAS inhibitor forward in colorectal cancer

...colorectal cancer patients who have progressed on two lines of treatment or more,” Marwan Fakih, City of Hope...
BioCentury | Sep 25, 2019
Targets & Mechanisms

Switching targets to avoid resistance to CAR Ts

...director of the Comprehensive Cancer Center and director of the Toni Stephenson Lymphoma Center at City of Hope...
...rescuing patients whose tumors have come back from initial CAR T cell therapy.” Larry Kwak, City of Hope...
...about six months. Targets: TNFRSF13c - tumor necrosis factor receptor superfamily member 13c Sandi Wong, Staff Writer City of Hope Tumor...
BioCentury | Aug 13, 2019
Company News

Aug. 13 Company Quick Takes: Pharming licenses Novartis' CDZ173; plus Novartis, Merck-Harvard, Mustang, J&J

...could be future targets for cancer treatments. CIRM grant to fund trial of Mustang therapy City of Hope...
...Li, Staff Writer MB-103 Sirturo, bedaquiline (TMC207, r207910) Zolgensma, onasemnogene abeparvovec-xioi, ScAAV9.CB.SMN (AVXS-101, charisma) California Institute for Regenerative Medicine (CIRM) City of Hope Harvard...
BioCentury | Aug 8, 2019
Emerging Company Profile

Akrevia: Masking immunotherapies en route to tumors

...Clackson. The company’s Aklusion technology, which is based on work of co-founder John Williams at City of Hope...
...substrate from the inactive akluded molecule, releasing the active drug. Williams is a professor in City of Hope’s...
...Cancer Clinical status: Preclinical Founded: 2016 by Simon Tomlinson, John Williams, Uli Rodeck University collaborators: City of Hope...
Items per page:
1 - 10 of 233
BioCentury | Sep 11, 2020
Translation in Brief

A compound to reduce adjuvanted vaccine side effects; an oncolytic virus to enable CAR T cells for solid tumors and more

...cytokines without compromising the vaccines’ immunogenicity or efficacy. City of Hope’s oncolytic virus-CAR T comboIn a paper in Science Translational Medicine, City of Hope...
...Priceman, an assistant professor in the department of hematology and hematopoietic cell transplantation, told BioCentury City of Hope...
...p50) – Nuclear factor of κ light polypeptide gene enhancer in B cells 1 BC Staff University of Chicago City of Hope University...
BioCentury | Aug 25, 2020
Management Tracks

Former head of gRED Varney joining Erasca; plus AAM, City of Hope, Immunovant, Kura, Illumina and more

...CEO of the National Pharmaceutical Council. The AAM represents generics and biosimilar manufacturers. Charles Brenner joined City of Hope...
...research department focused on the interface between cancer and diabetes in the U.S., according to City of Hope.Autoimmune...
...commercial officer. He was SVP, commercial North America at DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT). Robin Sawka Erasca Inc. City of Hope Kura...
BioCentury | Mar 7, 2020
Translation in Brief

Repurposing a protease inhibitor for COVID-19; plus City of Hope’s scorpion venom CAR T and Blaze’s tech for tissue-targeted steroid delivery

...cultured lung cells and other cell types. City of Hope’s chlorotoxin-based CAR T cells for glioblastoma A City of Hope...
...metalloproteinase 2 TMPRSS2 - Transmembrane protease serine 2 Hongjiang Li, Staff Writer, and Sandi Wong, Assistant Editor City of Hope Epidermal...
BioCentury | Feb 12, 2020
Tools & Techniques

NCATS, FDA meeting shines light on AAV manufacturing innovation

...amenable to high density culture systems. The latter were the focus of a presentation by City of Hope...
...of Health U.S. Food and Drug Administration (FDA) Touchlight Genetics Ltd. Cevec Pharmaceuticals GmbH Stanford University University of California San Francisco City of Hope gene...
BioCentury | Dec 14, 2019
Product Development

BCMA programs begin to find their niches

...study. Amrita Krishnan, director of the Judy and Bernard Briskin Center for Multiple Myeloma at City of Hope...
...all of these agents and it may mean that some are used sequentially.” Amrita Krishnan, City of Hope...
BioCentury | Nov 7, 2019
Clinical News

ALS group launches trial of digital app to track progression

...evaluate the benefits of acupuncture in recently diagnosed patients. TGen is an affiliate of the City of Hope. Erin...
BioCentury | Sep 30, 2019
Clinical News

Stable disease signal pushes Amgen KRAS inhibitor forward in colorectal cancer

...colorectal cancer patients who have progressed on two lines of treatment or more,” Marwan Fakih, City of Hope...
BioCentury | Sep 25, 2019
Targets & Mechanisms

Switching targets to avoid resistance to CAR Ts

...director of the Comprehensive Cancer Center and director of the Toni Stephenson Lymphoma Center at City of Hope...
...rescuing patients whose tumors have come back from initial CAR T cell therapy.” Larry Kwak, City of Hope...
...about six months. Targets: TNFRSF13c - tumor necrosis factor receptor superfamily member 13c Sandi Wong, Staff Writer City of Hope Tumor...
BioCentury | Aug 13, 2019
Company News

Aug. 13 Company Quick Takes: Pharming licenses Novartis' CDZ173; plus Novartis, Merck-Harvard, Mustang, J&J

...could be future targets for cancer treatments. CIRM grant to fund trial of Mustang therapy City of Hope...
...Li, Staff Writer MB-103 Sirturo, bedaquiline (TMC207, r207910) Zolgensma, onasemnogene abeparvovec-xioi, ScAAV9.CB.SMN (AVXS-101, charisma) California Institute for Regenerative Medicine (CIRM) City of Hope Harvard...
BioCentury | Aug 8, 2019
Emerging Company Profile

Akrevia: Masking immunotherapies en route to tumors

...Clackson. The company’s Aklusion technology, which is based on work of co-founder John Williams at City of Hope...
...substrate from the inactive akluded molecule, releasing the active drug. Williams is a professor in City of Hope’s...
...Cancer Clinical status: Preclinical Founded: 2016 by Simon Tomlinson, John Williams, Uli Rodeck University collaborators: City of Hope...
Items per page:
1 - 10 of 233